Liver

Alpha-fetoprotein (AFP) Tumour Marker for Liver Cancer: A Comprehensive Guide

featured image

Alpha-fetoprotein (AFP) is a protein that plays a crucial role during fetal development. In adults, elevated levels of AFP can be indicative of certain types of cancer, including liver cancer. This article explores the significance of AFP as a tumour marker, its role in the diagnosis and management of liver cancer, and the procedures involved in AFP testing.

What is Alpha-Fetoprotein (AFP)?

Alpha-fetoprotein (AFP) is a glycoprotein predominantly produced by the fetal liver and yolk sac during pregnancy. AFP levels in the blood typically decrease soon after birth and remain low in healthy adults. Elevated AFP levels can indicate various medical conditions, including liver disease and liver cancer.

The Role of AFP in Liver Cancer

Diagnostic Tool

AFP is commonly used as a tumour marker in the diagnosis of hepatocellular carcinoma (HCC), the most prevalent type of primary liver cancer. Elevated AFP levels can be an early indicator of liver cancer, prompting further diagnostic imaging and biopsy to confirm the presence of cancerous cells.

Monitoring Treatment

For people diagnosed with liver cancer, AFP levels are monitored regularly to assess the effectiveness of treatment. A significant drop in AFP levels often indicates a positive response to treatment, while rising levels may suggest tumour growth or recurrence.

What to Expect During the AFP Testing Procedure

Before the test, patients may be required to fast or avoid certain medications to ensure accurate results. The AFP test typically involves a simple blood draw, usually from a vein in the arm. The procedure is quick, takes less than five minutes, and is performed in a clinical setting such as a hospital or a diagnostic lab.

After the blood draw, patients can usually resume normal activities immediately. No significant side effects are associated with the test, though minor bruising at the puncture site may occur.

Understanding AFP Levels

Understanding AFP levels involves understanding the context and variability of the results:

  • Normal Levels: Healthy adults have AFP levels that are below 10 ng/mL.
  • Indicative of HCC: Levels exceeding 500 ng/mL are strongly indicative of hepatocellular carcinoma, particularly in patients with underlying conditions such as cirrhosis or chronic hepatitis.
  • Moderate Elevations: Levels that are moderately elevated may be associated with other liver conditions, including liver regeneration or active hepatitis.

Limitations of AFP as a Tumour Marker

False Positives and False Negatives

  • False Positives: Elevated AFP levels can occur in non-cancerous liver conditions like hepatitis and cirrhosis, leading to unnecessary anxiety and additional tests.
  • False Negatives: Not all liver cancer patients exhibit elevated AFP levels, especially in early stages, potentially allowing the cancer to go undetected.

Variability in AFP Levels

  • Individual Variability: Factors such as age, gender, and ethnicity can influence AFP levels, making it difficult to establish a universal threshold.
  • Tumour Characteristics: Some liver tumours produce little to no AFP, limiting its effectiveness as a marker for all liver cancers.

Limited Specificity

  • Non-specific Marker: Elevated AFP can also occur in other cancers and non-cancerous conditions, necessitating additional confirmatory tests for accurate diagnosis.

Conclusion

Alpha-fetoprotein (AFP) is an important tumour marker in the early detection and management of liver cancer. Regular AFP testing, especially for high-risk people, can lead to early diagnosis and improved treatment outcomes. However, it is important to interpret AFP levels alongside other diagnostic tools to ensure accurate diagnosis and effective monitoring of liver cancer.